Theriva Biologics (NYSEAMERICAN:TOVX) Trading Up 3.8% – Here’s Why

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX)’s share price was up 3.8% during trading on Thursday . The stock traded as high as $0.2621 and last traded at $0.2525. 1,535,853 shares changed hands during mid-day trading, an increase of 188% from the average session volume of 532,729 shares. The stock had previously closed at $0.2432.

Theriva Biologics Trading Up 3.8%

The company has a debt-to-equity ratio of 0.13, a current ratio of 1.13 and a quick ratio of 1.13. The firm has a fifty day simple moving average of $0.23 and a two-hundred day simple moving average of $0.25. The firm has a market capitalization of $8.52 million, a P/E ratio of -0.01 and a beta of 1.11.

Theriva Biologics (NYSEAMERICAN:TOVX) last issued its earnings results on Tuesday, August 11th. The company reported ($0.07) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Theriva Biologics

A hedge fund recently bought a new stake in Theriva Biologics stock. Two Sigma Investments LP acquired a new stake in shares of Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 61,837 shares of the company’s stock, valued at approximately $25,000. Two Sigma Investments LP owned about 0.64% of Theriva Biologics as of its most recent SEC filing. 6.17% of the stock is owned by institutional investors.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.